我院心力衰竭患者沙库巴曲缬沙坦应用情况调查  

Investigation of the Application Status of Sacubitril/valsartan in Patients with Heart Failure in Our Hospital

作　　者：叶东旭[1] 余儒桓 余守雅 岳云霄[1] 赵娅柯 Ye Dongxu;Yu Ruhuan;Yu Shouya;Yue Yunxiao;Zhao Yake(Clinical Pharmacy,the First People's Hospital of Pingdingshan,Henan Pingdingshan 467000,China;Department of Ultrasound Medicime,the First People's Hospital of Pingdingshan,Henan Pingdingshan 467000,China)

机构地区：[1]平顶山市第一人民医院临床药学科,河南平顶山467000 [2]平顶山市第一人民医院超声医学科,河南平顶山467000

出　　处：《中国药师》2021年第4期717-721,共5页China Pharmacist

摘　　要：目的:了解我院心力衰竭患者沙库巴曲缬沙坦的应用情况,为临床合理使用该药提供依据。方法:利用医院信息系统,回顾性分析2019年4~12月使用沙库巴曲缬沙坦的80例心力衰竭患者的基本信息,按照适应证、禁忌证、用法用量、药物转换、不良反应、靶剂量等评价标准,进行合理用药评价。结果:共纳入使用沙库巴曲缬沙坦的心力衰竭患者80例。存在无适应证用药的有42例(52.5%),无患者存在用药禁忌;用法用量不合理的有24例(30%);与血管紧张素受体转化酶抑制药(ACEI)或血管紧张素Ⅱ受体拮抗药(ARB)转换不合理的有6例(7.5%);发生药品不良反应的8例(10%)。达到靶剂量的有39例(48.75%)。结论:我院沙库巴曲缬沙坦的应用与国内外心力衰竭指南的推荐存在一定差距,主要表现在适应证、用法用量、禁忌证、与ACEI或ARB的转换等方面。提示临床药师可从这些方面切入,规范沙库巴曲缬沙坦的临床应用,为临床合理用药提供服务。Objective: To investigate the application status of sacubitril/valsartan in patients with heart failure in our hospital,and to provide basis for the rational use of the drug in clinic. Methods: Using the hospital information system,the basic information of 80 patients with heart failure who were treated with sacubitril/valsartan from April to December 2019 was collected and analyzed retrospectively. According to the evaluation criteria of indications,contraindications,usage and dosage,drug conversion,adverse reactions and target dose,the above indicators of rational drug use were evaluated. Results: A total of 80 patients with heart failure were treated with sacubitril/valsartan. Among them,42 cases(52.5%) were without indication,24 cases(30%) with unreasonable usage and dosage,6 cases(7.5%) with unreasonable conversion with ACEI or ARB drugs,8 cases(10%) with adverse drug reactions and 39 cases(48.75%) with target dose. Conclusion: There is a certain gap between the application of sacubitril/valsartan in our hospital and the requirements of heart failure guidelines at home and abroad,mainly in terms of indications,usage and dosage,contraindications and conversion with ACEI or ARB,etc. It is suggested that clinical pharmacists can take the above aspects as the breakthrough points to standardize the clinical application of sacubitril/valsartan and provide services for clinical rational drug use.

关 键 词：沙库巴曲缬沙坦 心力衰竭 临床应用 合理用药 

分 类 号：R972.1[医药卫生—药品]